taqman® assay for kras codon 12/13 mutations (TIB MOLBIOL)
90
Structured Review
TIB MOLBIOL
taqman® assay for kras codon 12/13 mutations
Taqman® Assay For Kras Codon 12/13 Mutations, supplied by TIB MOLBIOL, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/codon+13/taqman++assay+for+kras+codon+12+13+mutations/pm25632066-53-24-32
Average 90 stars, based on 1 article reviews
Taqman® Assay For Kras Codon 12/13 Mutations, supplied by TIB MOLBIOL, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/codon+13/taqman++assay+for+kras+codon+12+13+mutations/pm25632066-53-24-32
Average 90 stars, based on 1 article reviews
taqman® assay for kras codon 12/13 mutations - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Sequencing:Article Title: A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. Article Snippet: A KRASmutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer J. S. Chen1,, C. Hsu2,, N. J. Chiang3,4,5,, C. S. Tsai6,, H. H. Tsou7, S. F. Huang8, L. Y. Bai9, I. C. Chang8, H. S. Shiah10, C. L. Ho11, C. J. Yen4, K. D. Lee12, C. F. Chiu9, K. M. Rau13, M. S. Yu14, Y. Yang15, R. K. Hsieh16, J. Y. Chang3,4, Y. S. Shan17,, Y. Chao18, & L. T. Chen3,4,5,*, on behalf of the Taiwan Cooperative Oncology Group Division of Hematology and Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital and Chang Gung University, Taoyuan; Department of Oncology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei; National Institute of Cancer Research, National Health Research Institutes, Tainan; Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan; Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung; Division of Hematology and Oncology, Department of Internal Medicine, Tainan Municipal Hospital, Tainan; Division of Biostatistics and Bioinformatics, Institute of Population Health Sciences, National Health Research Institutes, Miaoli; Institute of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli; Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung; Taipei Cancer Center, Taipei Medical University Hospital, Taipei; Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, Taipei; Division of Hematology and Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chiayi; Division of Hematology and Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Kaohsiung; Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung; Division of Hematology and Oncology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung; Division of Hematology and Oncology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei; Department of Surgery, National Cheng Kung University Hospital, Tainan; Cancer Center, Taipei Veterans General Hospital, Taipei, Taiwan TaqMan Assay:Article Title: A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. Article Snippet: A KRASmutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer J. S. Chen1,, C. Hsu2,, N. J. Chiang3,4,5,, C. S. Tsai6,, H. H. Tsou7, S. F. Huang8, L. Y. Bai9, I. C. Chang8, H. S. Shiah10, C. L. Ho11, C. J. Yen4, K. D. Lee12, C. F. Chiu9, K. M. Rau13, M. S. Yu14, Y. Yang15, R. K. Hsieh16, J. Y. Chang3,4, Y. S. Shan17,, Y. Chao18, & L. T. Chen3,4,5,*, on behalf of the Taiwan Cooperative Oncology Group Division of Hematology and Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital and Chang Gung University, Taoyuan; Department of Oncology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei; National Institute of Cancer Research, National Health Research Institutes, Tainan; Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan; Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung; Division of Hematology and Oncology, Department of Internal Medicine, Tainan Municipal Hospital, Tainan; Division of Biostatistics and Bioinformatics, Institute of Population Health Sciences, National Health Research Institutes, Miaoli; Institute of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli; Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung; Taipei Cancer Center, Taipei Medical University Hospital, Taipei; Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, Taipei; Division of Hematology and Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chiayi; Division of Hematology and Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Kaohsiung; Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung; Division of Hematology and Oncology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung; Division of Hematology and Oncology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei; Department of Surgery, National Cheng Kung University Hospital, Tainan; Cancer Center, Taipei Veterans General Hospital, Taipei, Taiwan |